Search form

Search form

Children with T-cell acute lymphoblastic leukemia who carry a unique expression of five genes are likely to relapse, researchers said. The discovery could be used to create screening tests to identify patients who need more aggressive therapy to achieve complete remission, a study co-author said.

Related Summaries

An 80% rate of complete remission was found for patients with relapsed or refractory B-cell acute lymphoblastic leukemia who received anti-CD22 chimeric antigen receptor T-cell salvage therapy, according to a presentation at the American Society of Hematology meeting. A researcher reporting the results for 16 patients said the study team is considering how anti-CD22 CAR T-cell therapy would be combined with anti-CD19 treatment.

Children with T-cell acute lymphoblastic leukemia who carry a unique expression of five genes are likely to relapse, researchers said. The discovery could be used to create screening tests to identify patients who need more aggressive therapy to achieve complete remission, a study co-author said.

Children with T-cell acute lymphoblastic leukemia who carry a unique expression of five genes are likely to relapse, researchers said. The discovery could be used to create screening tests to identify patients who need more aggressive therapy to achieve complete remission, a study co-author said.

The American Cancer Society is aiming to recruit 500,000 volunteers for a new study that will focus on the genetic and environmental causes of cancer. This is the first time that the society will use blood samples from volunteers for a study. The researchers will store the blood samples so they can test them over time using emerging technologies and approaches. The study, which will monitor subjects for 30 years, so far has enrolled 70,000 participants.